Matches in Nanopublications for { ?s ?p "[Targeted ERBB2/HER2 inhibitors are approved by the U.S. Food and Drug Administration for the treatment of breast, gastric, and esophageal cancers that overexpress or amplify HER2/ERBB2, as measured by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- assertion description "[Targeted ERBB2/HER2 inhibitors are approved by the U.S. Food and Drug Administration for the treatment of breast, gastric, and esophageal cancers that overexpress or amplify HER2/ERBB2, as measured by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1245357.RAuiiUVLOw09uvrejE4C8GWuoDlHhAA_Ulxwi_0ymk9xI130_assertion description "[Targeted ERBB2/HER2 inhibitors are approved by the U.S. Food and Drug Administration for the treatment of breast, gastric, and esophageal cancers that overexpress or amplify HER2/ERBB2, as measured by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1245357.RAuiiUVLOw09uvrejE4C8GWuoDlHhAA_Ulxwi_0ymk9xI130_provenance.
- NP1245358.RAIHTg15DNAMtHOjLKTMGKFfy29ymPY82ll2wueVCfPO8130_assertion description "[Targeted ERBB2/HER2 inhibitors are approved by the U.S. Food and Drug Administration for the treatment of breast, gastric, and esophageal cancers that overexpress or amplify HER2/ERBB2, as measured by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1245358.RAIHTg15DNAMtHOjLKTMGKFfy29ymPY82ll2wueVCfPO8130_provenance.
- NP1245359.RA5L9fkHgkxl55wAZTz_IeIy9xzHRUSB1WBEFquAQoZbo130_assertion description "[Targeted ERBB2/HER2 inhibitors are approved by the U.S. Food and Drug Administration for the treatment of breast, gastric, and esophageal cancers that overexpress or amplify HER2/ERBB2, as measured by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1245359.RA5L9fkHgkxl55wAZTz_IeIy9xzHRUSB1WBEFquAQoZbo130_provenance.